Literature DB >> 26992418

A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine.

Nelson Leung1, Samih H Nasr2.   

Abstract

Monoclonal gammopathy is increasingly recognized as a cause of kidney injury. These renal conditions behave differently than ones without monoclonal gammopathy and require specific treatment. To avoid misdiagnosis, testing for paraprotein should be performed in addition to vasculitis and autoimmune diseases serologies in adults with unexplained AKI or proteinuria. Because the prevalence of monoclonal gammopathy is much more common than glomerular diseases, the nephrotoxicity of the monoclonal protein must be confirmed before cytotoxic therapy is initiated. This can only be done by a kidney biopsy. After a monoclonal gammopathy of renal significant is verified, the evaluation should then focus on the identification of the pathologic clone, because therapy is clone specific. We present this patient to illustrate the clinical presentation of a patient with renal dysfunction and a monoclonal gammopathy. This patient is also used to discuss the diagnostic process in detail when monoclonal gammopathy-associated renal disease is suspected.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  Acute Kidney Injury; Adult; Humans; MGRS; Paraproteins; glomerular disease; kidney biopsy; multiple myeloma; proteinuria; renal failure

Mesh:

Substances:

Year:  2016        PMID: 26992418      PMCID: PMC4891755          DOI: 10.2215/CJN.10641015

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  76 in total

1.  Coexistence of myeloma cast nephropathy, light chain deposition disease, and nonamyloid fibrils in a patient with multiple myeloma.

Authors:  Qi Qian; Nelson Leung; Jason D Theis; Ahmet Dogan; Sanjeev Sethi
Journal:  Am J Kidney Dis       Date:  2010-09-25       Impact factor: 8.860

Review 2.  Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management.

Authors:  T D Shanafelt; P Ghia; M C Lanasa; O Landgren; A C Rawstron
Journal:  Leukemia       Date:  2010-01-21       Impact factor: 11.528

3.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

4.  Recurrence of monoclonal IgA lambda glomerulonephritis in kidney allograft associated with multiple myeloma.

Authors:  Sandra M S Herrmann; Mahendra V Govani; Mary E Fidler; Samih H Nasr; Daniel Klink; Chirag Amin; Nelson Leung; Fernando C Fervenza
Journal:  Clin Nephrol       Date:  2015-10       Impact factor: 0.975

5.  Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.

Authors:  Sandra M S Herrmann; Morie A Gertz; Mark D Stegall; Angela Dispenzieri; Fernando C Cosio; Shaji Kumar; Martha Q Lacy; Patrick G Dean; Mikel Prieto; Steven R Zeldenrust; Francis K Buadi; Stephen J Russell; Scott L Nyberg; Suzanne R Hayman; David Dingli; Fernando C Fervenza; Nelson Leung
Journal:  Nephrol Dial Transplant       Date:  2011-05-04       Impact factor: 5.992

Review 6.  Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.

Authors:  Bilal Mohty; Jean El-Cheikh; Ibrahim Yakoub-Agha; Philippe Moreau; Jean-Luc Harousseau; Mohamad Mohty
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

7.  Automated multicapillary electrophoresis for analysis of human serum proteins.

Authors:  Cécile Gay-Bellile; Djaouida Bengoufa; Pascal Houze; Didier Le Carrer; Mourad Benlakehal; Bernard Bousquet; Bernard Gourmel; Thierry Le Bricon
Journal:  Clin Chem       Date:  2003-11       Impact factor: 8.327

8.  Urinary free light chain analysis by the Freelite immunoassay: a preliminary study in multiple myeloma.

Authors:  Thierry Le Bricon; Djaouida Bengoufa; Mourad Benlakehal; Bernard Bousquet; Danielle Erlich
Journal:  Clin Biochem       Date:  2002-10       Impact factor: 3.281

9.  Nephrotoxic potential of Bence Jones proteins.

Authors:  A Solomon; D T Weiss; A A Kattine
Journal:  N Engl J Med       Date:  1991-06-27       Impact factor: 91.245

10.  Screening panels for detection of monoclonal gammopathies.

Authors:  Jerry A Katzmann; Robert A Kyle; Joanne Benson; Dirk R Larson; Melissa R Snyder; John A Lust; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Clin Chem       Date:  2009-06-11       Impact factor: 8.327

View more
  1 in total

Review 1.  Acute kidney injury pathology and pathophysiology: a retrospective review.

Authors:  Joseph P Gaut; Helen Liapis
Journal:  Clin Kidney J       Date:  2020-10-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.